569250-U
Discovery® HS C18 (3 µm) HPLC Columns
L × I.D. 5 cm × 4.6 mm, HPLC Column
Synonym(s):
Discovery RP18 HPLC Column
About This Item
Recommended Products
Product Name
Discovery® HS C18 HPLC Column, 3 μm particle size, L × I.D. 5 cm × 4.6 mm
material
stainless steel column
Quality Level
Agency
suitable for USP L1
product line
Discovery®
feature
endcapped
manufacturer/tradename
Discovery®
packaging
1 ea of
extent of labeling
20% Carbon loading
parameter
≤70 °C temp. range
400 bar pressure (5801 psi)
Looking for similar products? Visit Product Comparison Guide
1 of 4
This Item | 568513-U | 568500-U | 568501-U |
---|---|---|---|
separation technique reversed phase | separation technique reversed phase | separation technique reversed phase | separation technique reversed phase |
L × I.D. 5 cm × 4.6 mm | L × I.D. 25 cm × 4 mm | L × I.D. 5 cm × 2.1 mm | L × I.D. 10 cm × 2.1 mm |
matrix active group C18 (octadecyl) phase | matrix active group C18 (octadecyl) phase | matrix active group C18 (octadecyl) phase | matrix active group C18 (octadecyl) phase |
particle size 3 μm | particle size 5 μm | particle size 5 μm | particle size 5 μm |
matrix silica gel, high purity, spherical particle platform, fully porous particle | matrix silica gel, high purity, spherical particle platform, fully porous particle | matrix silica gel, high purity, spherical particle platform, fully porous particle | matrix silica gel, high purity, spherical particle platform, fully porous particle |
pore size 120 Å | pore size 120 Å | pore size 120 Å | pore size 120 Å |
Application
- A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This study developed a robust RP-HPLC method to determine molnupiravir in various nanoformulations, showcasing its potential application in permeability studies and ensuring drug stability (Reçber et al., 2022) (Reçber et al., 2022).
- Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: This research presented an HPLC-UV method for analyzing terizidone in plasma, facilitating its use in pharmacokinetic studies of patients with drug-resistant tuberculosis (Mulubwa and Mugabo, 2018) (Mulubwa and Mugabo, 2018).
- Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: The study optimized an LC method for quantifying doxorubicin in plasma and urine, crucial for pharmacokinetic, biomedical, and drug monitoring therapy applications (Maliszewska et al., 2018) (Maliszewska et al., 2018).
Features and Benefits
- Stable, low bleed for LC-MS applications
- Scalable from analytical to preparatory
- Highly stable to ensure excellent run-to-run and lot-to-lot reproducibility
- Higher hydrophobicity for better resolution of difficult analytes
Legal Information
guard cartridge
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service